The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.
Abstract
CD19 is expressed on B cells from an early stage and in most B-cell malignancies, but not in hematopoietic stem cells or other normal tissues, thereby making it an attractive therapeutic target for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphomas. While CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapies, monoclonal antibodies, and antibody-drug conjugates are effective therapies for B-cell lymphomas, outcomes in the R/R setting may depend on exposure to prior treatments with the same antigen. There are limited data on the impact of sequencing these treatment modalities. This review highlights recent trial and real-world data focusing on the efficacy and safety of the CD19-targeted agents tafasitamab-lenalidomide and loncastuximab tesirine before and after CAR-T therapy in patients with R/R B-cell lymphoma and addresses the importance of assessing pretreatment target antigen levels as well as identifying common molecular mechanisms of treatment failure. Additionally, this analysis discusses the unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies, while providing expert clinical practice recommendations to optimize patient outcomes.
The efficacy of CAR T-cell therapy in patients with R/R HGBCL remains suboptimal, and high-grade morphology may help identify patients at particularly high risk of poor outcomes following CAR T-cell therapy.
T. Ochi, S. Makita, Anna Hiratsuka et al.· International Journal of Cli...· 0 citations
This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.
M. Kersten, M. Kuipers, P. Mutsaers et al.· The Lancet Haematology· 0 citations
In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.
Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al.· JAMA Oncology· 1 citation
This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
Xi Yang, Henry Dumke, Swetha Kambhampati Thiruvengadam et al.· Blood Advances· 0 citations
Current evidence remains largely preliminary and is limited by the paucity of randomized prospective trials, although relapse management is disease-specific and increasingly incorporates novel therapeutic agents, including bispecific antibodies (BsAbs) and other targeted therapies.
Martina Canichella, E. Abruzzese, Mariagiovanna Cefalo et al.· Cells· 0 citations
The achievement of a third complete response with the combination of daratumumab, high-dose cytarabine, and amsacrine in an 11-year-old patient with highly aggressive relapsed T-ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
Perrine Moyer, Baptiste Le Calvez, C. Mayeur-Rousse et al.· Pediatric Blood & Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.